Ipscs For Modeling Central Nervous System Disorders Volume 6

The series Advances in Stem Cell Biology is a timely and expansive collection of comprehensive information and new discoveries in the field of stem cell biology. iPSCs for Modeling Central Nervous System Disorders, Volume 6 addresses how induced pluripotent stem cells can be used to model various CNS disorders. Somatic cells can be reprogrammed into Induced pluripotent stem cells by the expression of specific transcription factors. These cells are transforming biomedical research in the last 15 years. The volume teaches readers about current advances in the field. This book describes the use of induced pluripotent stem cells to model several CNS diseases in vitro, enabling us to study the cellular and molecular mechanisms involved in different CNS pathologies. Further insights into these mechanisms will have important implications for our understanding of CNS disease appearance, development, and progression. In recent years, remarkable progress has been made in the obtention of induced pluripotent stem cells and their differentiation into several cell types, tissues and organs using state-of-art techniques. These advantages facilitated identification of key targets and definition of the molecular basis of several CNS disorders. This volume will cover what we know so far about the use of iPSCs to model different CNS disorders, such as: Alzheimer’s disease, Autism, Amyotrophic Lateral Sclerosis, Schizophrenia, Fragile X Syndrome, Spinal Muscular Atrophy, Rett Syndrome, Angelman syndrome, Parkinson`s Disease, Leber Hereditary Optic Neuropathy, Anorexia Nervosa, and more. The volume is written for researchers and scientists interested in stem cell therapy, cell biology, regenerative medicine, and neuroscience; and is contributed by world-renowned authors in the field. Provides overview of the fast-moving field of induced pluripotent stem cell technology and its application in neurobiology Covers the following CNS diseases: Alzheimer’s disease, Autism, Amyotrophic Lateral Sclerosis, Schizophrenia, Fragile X Syndrome, Spinal Muscular Atrophy, Rett Syndrome, Angelman syndrome, Parkinson`s Disease, Leber Hereditary Optic Neuropathy, Anorexia Nervosa, and more Contains description of cutting-edge research on the development of disease-specific human pluripotent stem cells. These cells allow us to study cellular and molecular processes involved in several CNS human diseases

iPSCs - State of the Science, Volume Sixteen, the latest release in the Advances in Stem Cell Biology series, is an expansive collection of information and new discoveries in the field. This volume addresses the importance of induced pluripotent stems cells and how can they be derived from different sources. It addresses advances in research in induced pluripotent stem cells from alternate sources, such as spermatogonial stem cells, ovarian tissue, cancer cells, and many other sources. It is written for researchers and scientists in stem cell therapy, cell biology, regenerative medicine and organ transplantation, and is contributed by world-renowned authors. Provides an overview of the fast-moving field of stem cell biology and function, regenerative medicine and therapeutics Covers iPSCs derived from amniotic fluid, oral tissue derived iPSCs, muse cells, postmortem tissue, and much more Contributed by world-renowned experts in the field

The series Advances in Stem Cell Biology is a timely and expansive collection of comprehensive information and new discoveries in the field of stem cell biology. iPSCs - Novel Concepts, Volume 15 addresses how important induced pluripotent stems cells are and how can they can help treat certain diseases. Somatic cells can be reprogrammed into induced pluripotent stem cells by the expression of specific transcription factors. These cells have been transforming biomedical research over the last 15 years. This volume will address the advances in research of how induced pluripotent stem cells are being used for treatment of different disorders, such as liver disease, type-1 diabetes, Parkinson’s disease, macular degeneration of the retina and much more. The volume is written for researchers and scientists in stem cell therapy, cell biology, regenerative medicine and organ transplantation; and is contributed by world-renowned authors in the field. Provides overview of the fast-moving field of stem cell biology and function, regenerative medicine and therapeutics Covers spinal cord injuries, type-1 diabetes, liver disease, Parkinson’s disease, graft vs. host disease, and much more Contributed by world-renown experts in the field

Neurodevelopmental Disorders, the latest release in the Comprehensive Developmental Neuroscience series, presents the most thorough coverage available, addressing all aspects on how the nervous system and its components develop. This book brings together the latest research in this rapidly evolving field, with section editors discussing the technological advances that are enabling the pursuit of new research on brain development. This volume focuses on neurodevelopmental disorders in humans and experimental organisms. Particular attention is paid to the effects of abnormal development and on new psychiatric/neurological treatments being developed based on our increased understanding of developmental mechanisms. Features leading experts in various subfields as section editors and article authors Presents articles that have been peer reviewed to ensure accuracy, thoroughness and scholarship Covers disorders of the nervous system that arise through defects in neural development

The 3rd World Congress on Genetics, Geriatrics, and Neurodegenerative Disease Research (GeNeDis 2018), focuses on recent advances in genetics, geriatrics, and neurodegeneration, ranging from basic science to clinical and pharmaceutical developments. It also provides an international forum for the latest scientific discoveries, medical practices, and care initiatives. Advanced information technologies are discussed, including the basic research, implementation of medico-social policies, and the European and global issues in the funding of long-term care for elderly people.

Features information on mental disorders as well as on treatment and procedures relating to those illnesses.

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

A discussion of all the key issues in the use of human pluripotent stem cells for treating degenerative diseases or for replacing tissues lost from trauma. On the practical side, the topics range from the problems of deriving human embryonic stem cells and driving their differentiation along specific lineages, regulating their development into mature cells, and bringing stem cell therapy to clinical trials. Regulatory issues are addressed in discussions of the ethical debate surrounding the derivation of human embryonic stem cells and the current policies governing their use in the United States and abroad, including the rules and conditions regulating federal funding and questions of intellectual property.